Combination therapy with the anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody durvalumab (D) and etoposide plus cisplatin or carboplatin (EP) is a first-line standard of care for ES-SCLC [8] based on the results of the randomized, open-label, phase 3 CASPIAN trial (NCT03043872) [9, 10]. This evidence concerns the gene CD274 and small cell lung carcinoma.